ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 221 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,261,238 | +47819.4% | 187,964 | -36.9% | 0.00% | -100.0% |
| Q1 2023 | $2,632 | -67.2% | 298,041 | -71.6% | 0.00% | -50.0% |
| Q4 2022 | $8,013 | -99.9% | 1,048,869 | +32.5% | 0.00% | +33.3% |
| Q3 2022 | $5,638,000 | +5.9% | 791,824 | +20.4% | 0.00% | 0.0% |
| Q2 2022 | $5,322,000 | -35.0% | 657,833 | +11.5% | 0.00% | -25.0% |
| Q1 2022 | $8,187,000 | +93.0% | 589,825 | +290.1% | 0.00% | +100.0% |
| Q4 2021 | $4,242,000 | +170.7% | 151,185 | +227.9% | 0.00% | +100.0% |
| Q3 2021 | $1,567,000 | +26.3% | 46,107 | +51.8% | 0.00% | 0.0% |
| Q2 2021 | $1,241,000 | -38.9% | 30,372 | -39.8% | 0.00% | 0.0% |
| Q1 2021 | $2,030,000 | -71.3% | 50,416 | -57.8% | 0.00% | -80.0% |
| Q4 2020 | $7,071,000 | +1082.4% | 119,586 | +497.9% | 0.01% | +400.0% |
| Q4 2019 | $598,000 | -88.7% | 20,000 | -88.3% | 0.00% | -87.5% |
| Q3 2019 | $5,284,000 | -84.5% | 171,018 | -75.8% | 0.01% | -84.3% |
| Q2 2019 | $34,171,000 | – | 707,467 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |